Portfolio Companies

Selecta Biosciences, Inc. & Selecta RUS

Vaccines Based on Selecta Biosciences’ tSVPТМ Nanoplatform

Operating Factories

Shareholders in Portfolio Company 
RUSNANO, Flagship Ventures, Polaris Venture Partners, OrbiMed Advisors, NanoDimension, other investors

Industry Sector 
Innovative Nanobiopharmaceutics

Production Location 
Khimki, Moscow Oblast
Jobs created: 20

Investment Started:  2011

Development and commercialization of an entirely new class of targeted vaccines that induce antigen-specific immune activation or antigen-specific immune tolerance for therapeutic and prophylactic applications

Selecta Biosciences, Inc. is a leader in development of synthetic nanovaccines and immunotherapies. Selecta’s lead drug candidate, SEL-068, has entered human clinical studies as a vaccine for smoking cessation and relapse prevention. Other drug development programs include universal human papillomavirus vaccine, universal influenza vaccine, malaria vaccine, and type 1 diabetes therapeutic vaccine.

Selecta’s patented technology originated in laboratories at Harvard Medical School under the direction of Professor Omid Farokhzad, MD and in laboratories at MIT under the direction of Professor Robert S. Langer. Professor Langer is a renowned scientist and a recipient of the National Medal of Science, the most prestigious honor for scientists bestowed by the United States, and an author of approximately 850 patents issued or pending worldwide. Professor Ulrich von Andrian, MD, PhD, head of the immunopathology laboratory at Harvard Medical School, is also a founder of Selecta.

This project enables Selecta Biosciences to open a laboratory and a manufacturing facility in Russia through a Russian subsidiary. By broadening its scientific and financial bases, Selecta Biosciences will be able to accelerate vaccine development. It gains access to rapidly growing pharmaceutical markets in Russia and the CIS and maximizes its technical platforms for creating new vaccines. The portfolio company will establish full-cycle development of pharmaceuticals—from research and testing through production and commercialization.

Areas of application

  • Prevention and treatment of cancers and infectious and autoimmune diseases
  • Therapies for nicotine dependence


  • Healthcare providers and their patients

Competitive advantages

  • A new pharmaceutical platform for prophylactic and therapeutic vaccines
  • Optimal immunological response
  • Minimal side effects
  • Low cost of production